Acadia Pharmaceuticals | ACAD - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
ALKERMES USD 264.59M 77.4M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Cara Therapeutics USD 2.19M 2.45M 2025-09
Corcept Therapeutics USD 128.04M 13.3M 2026-03
Cytokinetics USD 104.9M 13.17M 2026-03
Eisai JPY 119.54B 7.82B 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Incyte USD 328.1M 62.31M 2026-03
J&J USD 6.03B 719M 2026-03
Moderna USD 173M 135M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Prothena USD 7.65M 5.59M 2025-12
PTC Therapeutics USD 73.89M 13.31M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03